Cardio3 BioSciences acquires Corquest Medical Inc.

07-Nov-2014 - Cardio3 BioSciences (C3BS) announced that it has acquired U.S.-based CorQuest Medical Inc. CorQuest Medical specializes in the development of devices and technologies for cardiac surgery. CorQuest’s technology is designed to enable cardiologists to take a unique access route directly to the ...

Cardio3 BioSciences appoints Dr. Warren Sherman as Chief Medical Officer

27-Oct-2014 - Cardio3 BioSciences (C3BS) announced the appointment of Dr. Warren Sherman as Chief Medical Officer, effective as of 1 November 2014. In this new role, Dr. Sherman will leverage his deep expertise in the cardiovascular and cell therapy fields to support the continued development of Cardio3 ...

Cardio3 BioSciences Receives Authorization for Phase III Clinical Trial in Regenerative Medicine for Heart Failure

26-Nov-2012 - Cardio3 BioSciences (C3BS) announced it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium. This represents a ...

Cardio3 BioSciences Appoints Dr. Alexander Milstein as Vice President of Clinical Development

22-Aug-2012 - Cardio3 BioSciences (C3BS) announced the appointment of Dr. Alexander Milstein as Vice President of Clinical Development.Dr. Milstein brings to the Company extensive industry experience, including leading the design and execution of global clinical strategies for product approvals and competitive ...

Cardio3 BioSciences Granted GMP Certification

16-Apr-2012 - Cardio3 BioSciences (C3BS) announced that it has been granted Good Manufacturing Practice (GMP) Certification for its new production facilities in Mont-Saint-Guibert. Certification was granted by the Federal Agency for Medicines and Health Products (FAMHP), the authority responsible for the ...

Cardio3 BioSciences Receives ISO-13485 Certification

02-Mar-2012 - Cardio3BioSciences announced that it has been certified ENISO13485:2003 bythe National Standards Authority of Ireland. The ISO certification acknowledges that Cardio3BioSciences has been assessed and deemed to comply with the requirements of the ISO standard with respect to the design, ...

Cardio3 BioSciences Establishes US Subsidiary in Rochester, MN

27-Sep-2011 - Cardio3 BioSciences announced that it has established a subsidiary, Cardio3 BioSciences, Inc. in Rochester, Minnesota.Cardio3 BioSciences has advanced the development of its core revolutionary technology of adult autologous stem cell commitment to cardiac lineage C3BS-CQR-1 (C-Cure®) for the ...

Cardio3 BioSciences Announces Results of the C-Cure Phase II Clinical Trial

Positive Results for Innovative Heart-Specified Stem Cell Therapy Underscores Generalized Therapeutic Benefit in Heart Failure

07-Apr-2011 - Cardio3 BioSciences presented detailed data from the Phase II clinical trial of C3BS-CQR-1 (C-Cure®), its novel stem cell therapy for ischemic cardiomyopathy, at the 60th annual American College of Cardiology in New Orleans, USA.The data were presented by Dr. Jozef Bartunek, Associate Director of ...

Cardio3 BioSciences Appoints Drs Jan Andersson and Louise Proulx to its Board of Directors

25-Feb-2011 - Cardio3 BioSciences announced the appointment of Dr Jan Andersson and Dr Louise Proulx as Independent Directors.Jan Andersson, MD, PhD, is currently Vice-President of Karolinska Institutet (Sweden) and a Professor in Infectious Diseases at Karolinska University Hospital (Sweden). Dr Andersson has ...

Cardio3 BioSciences Announces Positive Outcome of the C-Cure Phase II Clinical Trial in Heart Failure Patients

19-Nov-2010 - Cardio3 BioSciences announced positive six-month results, including significant functional and clinical benefit, from the Phase II clinical trial of its development programme C-Cure®, designed as a novel stem cell therapy for heart failure based on breakthrough technology. Forty-five patients ...